Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHENOGENE-1A as Adjuvant Treatment in Mild to Moderate ALS
NCT07142291Phase 2Recruiting
- Start
- Nov 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of PHENOGENE-1A in amyotrophic lateral sclerosis (ALS). Started Nov 2025; status: recruiting.
02
Drugs
PHENOGENE-1A
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07142291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142291.